Minimum effective dose of ropivacaine for ulrtasound-guided sciatic nerve block

Study on the minimum effective dose of ropivacaine for sciatic nerve block

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300067788

Enrollment

Unknown

Registered

2023-01-27

Start date

2023-01-21

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polydactyly, syndactylia

Interventions

Test group:ropivacaine

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1.Children who are scheduled to undergo calf and foot surgery in Children's Hospital of Chongqing Medical University; 2.Children aged 0-18 years when included in ASA grade I-II.

Exclusion criteria

Exclusion criteria: 1. Abnormal coagulation function; 2. The presence of lower limb nerve injury; 3. The puncture site has a history of infection; 4. Known allergy to ropivacaine; 5. A history of upper respiratory tract infection; 6. Parents refuse to participate in the study.

Design outcomes

Primary

Measure	Time frame
50% minimum effective dose;90% minimum effective dose;	—

Secondary

Measure	Time frame
Complication;Success rate;	—

Countries

China

Contacts

Public ContactTu Shengfen

Department of Surgical anaesthesia, Children's Hospital of Chongqing Medical University

519194496@qq.com+86 139 8341 6114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026